This little-known biopharma stock has 60% upside potential, Goldman Sachs says
[ad_1] Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs…